Exenatide twice-daily does not affect renal function or albuminuria compared to titrated insulin glargine in patients with type 2 diabetes mellitus: A post-hoc analysis of a 52-week randomised trial.

Muskiet MHA, Bunck MC, Heine RJ, Cornér A, Yki-Järvinen H, Eliasson B, Joles JA, Diamant M, Tonneijck L, van Raalte DH

Diabetes research and clinical practice9 May 2019Cited by 17 (Europe PMC)

PMID31078666DOI10.1016/j.diabres.2019.05.001PepBankPUB-31078666

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

9 results from studies that gave the peptide. 9 results from people.

01HumanRandomized controlled trialEfficacy outcome
In overweight patients with type 2 diabetes, HbA1c reductions were similar with exenatide and insulin glargine.
In plain wordsIn overweight patients with type 2 diabetes, exenatide and insulin glargine lowered HbA1c similarly.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeHbA1c reduction
Study
n = 54
Comparator
titrated insulin glargine
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 µg twice daily · 52 weeksAs given in this study (human).
Measurements
HbA1c change
−0.8%
exenatide
HbA1c change
−0.79%
insulin glargine
HbA1c treatment difference
0.02%
exenatide versus insulin glargine
Source sentences
Summary
HbA1c-reductions were similar with exenatide (mean ± SEM -0.80 ± 0.10%) and iGlar (-0.79 ± 0.14%; treatment-difference 0.02%; 95% CI -0.31 to 0.42%).
1 context sentence(design, population, supporting numbers)
Summary · context
We post-hoc evaluated renal outcome-data of 54 overweight T2DM patients (mean  ± SD age 60 ± 8 years, HbA1c 7.5 ± 0.9%, eGFR 86 ± 16 mL/min/1.73 m², median [IQR] urinary albumin-to-creatinine-ratio (UACR) 0.75 [0.44-1.29] mg/mmol) randomised to exenatide 10 µg twice-daily or titrated iGla…
Report a problemFND-3107866601
02HumanRandomized controlled trialEfficacy outcome
In overweight patients with type 2 diabetes, creatinine clearance change did not differ between exenatide and insulin glargine.
In plain wordsIn overweight patients with type 2 diabetes, creatinine clearance changes did not differ between exenatide and insulin glargine.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeCreatinine clearance change
Study
n = 54
Comparator
titrated insulin glargine
Outcome group
Kidney function · Kidney and urinary
Studied dose
10 µg twice daily · 52 weeksAs given in this study (human).
Source sentences
Summary
Change from baseline to Week-52 in CrCl, UAE or UACR did not statistically differ; only iGlar reduced albuminuria (P < 0.05; within-group).
1 context sentence(design, population, supporting numbers)
Summary · context
We post-hoc evaluated renal outcome-data of 54 overweight T2DM patients (mean  ± SD age 60 ± 8 years, HbA1c 7.5 ± 0.9%, eGFR 86 ± 16 mL/min/1.73 m², median [IQR] urinary albumin-to-creatinine-ratio (UACR) 0.75 [0.44-1.29] mg/mmol) randomised to exenatide 10 µg twice-daily or titrated iGla…
Report a problemFND-3107866602
03HumanRandomized controlled trialEfficacy outcome
In overweight patients with type 2 diabetes, urinary albumin excretion change did not differ between exenatide and insulin glargine.
In plain wordsIn overweight patients with type 2 diabetes, urinary albumin excretion changes did not differ between exenatide and insulin glargine.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeUrinary albumin excretion change
Study
n = 54
Comparator
titrated insulin glargine
Outcome group
Kidney function · Kidney and urinary
Studied dose
10 µg twice daily · 52 weeksAs given in this study (human).
Source sentences
Summary
Change from baseline to Week-52 in CrCl, UAE or UACR did not statistically differ; only iGlar reduced albuminuria (P < 0.05; within-group).
1 context sentence(design, population, supporting numbers)
Summary · context
We post-hoc evaluated renal outcome-data of 54 overweight T2DM patients (mean  ± SD age 60 ± 8 years, HbA1c 7.5 ± 0.9%, eGFR 86 ± 16 mL/min/1.73 m², median [IQR] urinary albumin-to-creatinine-ratio (UACR) 0.75 [0.44-1.29] mg/mmol) randomised to exenatide 10 µg twice-daily or titrated iGla…
Report a problemFND-3107866603
04HumanRandomized controlled trialEfficacy outcome
In overweight patients with type 2 diabetes, UACR change did not differ between exenatide and insulin glargine.
In plain wordsIn overweight patients with type 2 diabetes, urine albumin-to-creatinine changes did not differ between exenatide and insulin glargine.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeUrinary albumin-to-creatinine ratio change
Study
n = 54
Comparator
titrated insulin glargine
Outcome group
Kidney function · Kidney and urinary
Studied dose
10 µg twice daily · 52 weeksAs given in this study (human).
Source sentences
Summary
Change from baseline to Week-52 in CrCl, UAE or UACR did not statistically differ; only iGlar reduced albuminuria (P < 0.05; within-group).
1 context sentence(design, population, supporting numbers)
Summary · context
We post-hoc evaluated renal outcome-data of 54 overweight T2DM patients (mean  ± SD age 60 ± 8 years, HbA1c 7.5 ± 0.9%, eGFR 86 ± 16 mL/min/1.73 m², median [IQR] urinary albumin-to-creatinine-ratio (UACR) 0.75 [0.44-1.29] mg/mmol) randomised to exenatide 10 µg twice-daily or titrated iGla…
Report a problemFND-3107866604
05HumanRandomized controlled trialEfficacy outcome
In overweight patients with type 2 diabetes, ensuing eGFR trajectories did not differ between exenatide and insulin glargine.
In plain wordsIn overweight patients with type 2 diabetes, later kidney filtration changes did not differ between exenatide and insulin glargine.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeeGFR trajectory
Study
n = 54
Comparator
titrated insulin glargine
Outcome group
Kidney function · Kidney and urinary
Studied dose
10 µg twice daily · 52 weeksAs given in this study (human).
Source sentences
Summary
eGFR decreased from baseline to Week-4 with exenatide (-3.9 ± 2.1 mL/min/1.73 m²; P = 0.069) and iGlar (-2.7 ± 1.2 mL/min/1.73 m²; P = 0.034), without treatment-differences in ensuing trajectory.
1 context sentence(design, population, supporting numbers)
Summary · context
We post-hoc evaluated renal outcome-data of 54 overweight T2DM patients (mean  ± SD age 60 ± 8 years, HbA1c 7.5 ± 0.9%, eGFR 86 ± 16 mL/min/1.73 m², median [IQR] urinary albumin-to-creatinine-ratio (UACR) 0.75 [0.44-1.29] mg/mmol) randomised to exenatide 10 µg twice-daily or titrated iGla…
Report a problemFND-3107866606
06HumanRandomized controlled trialEfficacy outcome
In overweight patients with type 2 diabetes, exenatide reduced body weight versus insulin glargine by 5.4 kg.
In plain wordsIn overweight patients with type 2 diabetes, exenatide reduced body weight more than insulin glargine.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBody weight
Study
n = 54
Comparator
titrated insulin glargine
Outcome group
Body weight · Metabolic and weight
Studied dose
10 µg twice daily · 52 weeksAs given in this study (human).
Measurements
Body weight difference
−5.4 kg
exenatide versus insulin glargine
Source sentences
Summary
Exenatide versus iGlar reduced bodyweight (-5.4 kg; 2.9-7.9; P < 0.001), but did not affect blood pressure, lipids or plasma uric acid.
1 context sentence(design, population, supporting numbers)
Summary · context
We post-hoc evaluated renal outcome-data of 54 overweight T2DM patients (mean  ± SD age 60 ± 8 years, HbA1c 7.5 ± 0.9%, eGFR 86 ± 16 mL/min/1.73 m², median [IQR] urinary albumin-to-creatinine-ratio (UACR) 0.75 [0.44-1.29] mg/mmol) randomised to exenatide 10 µg twice-daily or titrated iGla…
Report a problemFND-3107866607
07HumanRandomized controlled trialEfficacy outcome
In overweight patients with type 2 diabetes, exenatide did not affect blood pressure versus insulin glargine.
In plain wordsIn overweight patients with type 2 diabetes, blood pressure did not differ between exenatide and insulin glargine.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeBlood pressure
Study
n = 54
Comparator
titrated insulin glargine
Outcome group
Blood pressure · Cardiovascular
Studied dose
10 µg twice daily · 52 weeksAs given in this study (human).
Source sentences
Summary
Exenatide versus iGlar reduced bodyweight (-5.4 kg; 2.9-7.9; P < 0.001), but did not affect blood pressure, lipids or plasma uric acid.
1 context sentence(design, population, supporting numbers)
Summary · context
We post-hoc evaluated renal outcome-data of 54 overweight T2DM patients (mean  ± SD age 60 ± 8 years, HbA1c 7.5 ± 0.9%, eGFR 86 ± 16 mL/min/1.73 m², median [IQR] urinary albumin-to-creatinine-ratio (UACR) 0.75 [0.44-1.29] mg/mmol) randomised to exenatide 10 µg twice-daily or titrated iGla…
Report a problemFND-3107866608
08HumanRandomized controlled trialEfficacy outcome
In overweight patients with type 2 diabetes, exenatide did not affect lipids versus insulin glargine.
In plain wordsIn overweight patients with type 2 diabetes, lipids did not differ between exenatide and insulin glargine.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeLipids
Study
n = 54
Comparator
titrated insulin glargine
Outcome group
Lipids · Metabolic and weight
Studied dose
10 µg twice daily · 52 weeksAs given in this study (human).
Source sentences
Summary
Exenatide versus iGlar reduced bodyweight (-5.4 kg; 2.9-7.9; P < 0.001), but did not affect blood pressure, lipids or plasma uric acid.
1 context sentence(design, population, supporting numbers)
Summary · context
We post-hoc evaluated renal outcome-data of 54 overweight T2DM patients (mean  ± SD age 60 ± 8 years, HbA1c 7.5 ± 0.9%, eGFR 86 ± 16 mL/min/1.73 m², median [IQR] urinary albumin-to-creatinine-ratio (UACR) 0.75 [0.44-1.29] mg/mmol) randomised to exenatide 10 µg twice-daily or titrated iGla…
Report a problemFND-3107866609
09HumanRandomized controlled trialEfficacy outcome
In overweight patients with type 2 diabetes, exenatide did not affect plasma uric acid versus insulin glargine.
In plain wordsIn overweight patients with type 2 diabetes, plasma uric acid did not differ between exenatide and insulin glargine.
Peptide
Exenatide (exendin-4)
Outcome
No significant changePlasma uric acid
Study
n = 54
Comparator
titrated insulin glargine
Outcome group
Blood biochemical markers · Metabolic and weight
Studied dose
10 µg twice daily · 52 weeksAs given in this study (human).
Source sentences
Summary
Exenatide versus iGlar reduced bodyweight (-5.4 kg; 2.9-7.9; P < 0.001), but did not affect blood pressure, lipids or plasma uric acid.
1 context sentence(design, population, supporting numbers)
Summary · context
We post-hoc evaluated renal outcome-data of 54 overweight T2DM patients (mean  ± SD age 60 ± 8 years, HbA1c 7.5 ± 0.9%, eGFR 86 ± 16 mL/min/1.73 m², median [IQR] urinary albumin-to-creatinine-ratio (UACR) 0.75 [0.44-1.29] mg/mmol) randomised to exenatide 10 µg twice-daily or titrated iGla…
Report a problemFND-3107866610

Studies that did not test the peptide alone1

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

10HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In overweight patients with type 2 diabetes, early eGFR decreased from baseline with both treatments, nonsignificantly with exenatide.
In plain wordsIn patients with type 2 diabetes, early kidney filtration decreased with both treatments, nonsignificantly with exenatide.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeEarly eGFR change
Study
n = 54
Comparator
baseline
Outcome group
Kidney function · Kidney and urinary
Measurements
eGFR change from baseline to Week 4
−3.9 mL/min/1.73 m²
exenatide
eGFR change from baseline to Week 4
−2.7 mL/min/1.73 m²
insulin glargine
Source sentences
Summary
eGFR decreased from baseline to Week-4 with exenatide (-3.9 ± 2.1 mL/min/1.73 m²; P = 0.069) and iGlar (-2.7 ± 1.2 mL/min/1.73 m²; P = 0.034), without treatment-differences in ensuing trajectory.
1 context sentence(design, population, supporting numbers)
Summary · context
We post-hoc evaluated renal outcome-data of 54 overweight T2DM patients (mean  ± SD age 60 ± 8 years, HbA1c 7.5 ± 0.9%, eGFR 86 ± 16 mL/min/1.73 m², median [IQR] urinary albumin-to-creatinine-ratio (UACR) 0.75 [0.44-1.29] mg/mmol) randomised to exenatide 10 µg twice-daily or titrated iGla…
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-3107866605

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT00097500

Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes

AstraZenecan = 69Sept 2004 to Dec 2009

Type 2 Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 7 Apr 2015

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.